Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MicroPort Scientific ( (HK:0853) ) has issued an announcement.
Shanghai MicroPort Endovascular MedTech (Endovastec), 40.32% owned by MicroPort Scientific, reported unaudited revenue of RMB1.35 billion for the twelve months ended 31 December 2025, up 12% year on year. Net profit attributable to Endovastec’s equity owners rose 12.2% to RMB563.2 million, with total assets increasing 8.1% to RMB4.64 billion and equity attributable to equity owners up 7.5%.
The figures, prepared under PRC accounting standards, underscore steady growth at Endovastec but are limited to this subsidiary and do not represent the full performance of the MicroPort group. The company cautioned investors that the data are unaudited, may include intra-group transactions, and should be interpreted carefully when assessing the group’s overall financial position and valuing its securities.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
More about MicroPort Scientific
MicroPort Scientific Corporation is a Cayman Islands-incorporated medical technology company with a significant stake in Shanghai MicroPort Endovascular MedTech (Endovastec), a listed entity on Shanghai’s STAR Market. Endovastec focuses on endovascular medical devices, and its financial results are consolidated into MicroPort’s group accounts, reflecting its strategic role in the group’s medtech portfolio.
Average Trading Volume: 15,059,338
Technical Sentiment Signal: Hold
Current Market Cap: HK$21.53B
Learn more about 0853 stock on TipRanks’ Stock Analysis page.